The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | The impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel
Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, discusses a real-world study evaluating the impact of various forms of bridging therapy (BT) on the outcomes of patients with relapsed/refractory (R/R) multiple myeloma being treated with idecabtagene vicleucel (ide-cel). Dr Anderson highlights the impact of these forms of BT on progression-free and overall survival (PFS; OS), and comments on the importance of bringing CAR-T therapy into earlier lines. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory/consultant to BMS, Janssen, Celgene, AbbVie, GSK
